Results 201 to 210 of about 10,368 (217)

Dupilumab

Reactions Weekly, 2018
  +5 more sources

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Allergy: European Journal of Allergy and Clinical Immunology, 2022
Daphne Bakker, Marjolein De Bruin-Weller, Lotte Spekhorst   +2 more
exaly  

Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases

Clinical Reviews in Allergy and Immunology, 2022
Marie Tauber, Anna Kychygina, Myriam Cassagne   +2 more
exaly  

Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis

Journal of Dermatological Treatment, 2023
Kui Young Park, Hye Sung Han, Jun Ki Hong   +2 more
exaly  

Rosacea associated with dupilumab therapy

Journal of Dermatological Treatment, 2021
Vivian Y Shi, Aleksi Hendricks
exaly  

Dupilumab

Reactions Weekly, 2019
openaire   +2 more sources

Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management

Expert Review of Respiratory Medicine, 2022
Marco Caminati, Pierluigi Paggiaro, Patrick Pintér   +2 more
exaly  

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Lieneke Fm Ariëns, Edward Knol, Daphne Bakker   +2 more
exaly  

Mechanisms of Dupilumab

Clinical and Experimental Allergy, 2020
Talal Chatila, Hani Harb
exaly  

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Clinical and Experimental Allergy, 2021
Jennifer Davidson Hamilton, Allen Radin, Naimish Patel   +2 more
exaly